Veliparib, Pembrolizumab, and Combination Chemotherapy in Treating Patient With Locally
Advanced Rectal Cancer
Basic Study Information
Purpose:Location: University of Rochester
This randomized phase II trial studies how well veliparib or pembrolizumab work with
combination chemotherapy and radiation therapy in treating patients with rectal cancer
has spread from where it started to nearby tissue or lymph nodes (locally advanced).
Veliparib may stop the growth of tumor cells by blocking some of the enzymes needed
growth. Monoclonal antibodies, such as pembrolizumab, may interfere with the ability
cells to grow and spread. Drugs used in chemotherapy, such as modified (m)FOLFOX6
work in different ways to stop the growth of tumor cells, either by killing the cells,
stopping them from dividing, or by stopping them from spreading. Radiation therapy
high-energy x-rays to kill tumor cells and shrink tumors. Giving veliparib or pembrolizumab
with combination chemotherapy and radiation therapy may kill more tumor cells, make
smaller, and reduce the amount of normal tissue that needs to be removed.
Study Contact InformationStudy Coordinator: Site Public Contact
Additional Study Details
Trial Not Found
The study you are looking for is not active at this time.
Return to Search